China Pharma Holdings (CPHI) Non Operating Income (2011 - 2026)
China Pharma Holdings (CPHI) posted Non Operating Income of -$25884.0 for Q1 2026, down 17.98% on a QoQ basis from -$21940.0 in Q4 2025, and up 3.97% year-over-year from -$24895.7 in Q1 2025.
China Pharma Holdings (CPHI) Non Operating Income (2011 - 2026) Analysis & Trends
China Pharma Holdings' Non Operating Income history runs 12 years deep, the most recent figure standing at -$25884.0 for Q1 2026.
- Quarterly Non Operating Income rose 3.97% year-over-year to -$25884.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52592.0 (up 139.07% YoY) and the FY2025 annual result came in at $51522.0, up 134.93% from the prior year.
- Non Operating Income was -$25884.0 for Q1 2026 at China Pharma Holdings, down from -$21940.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $123753.0 in Q2 2025 and bottomed at -$136721.0 in Q2 2023.
- A 5-year average of -$51336.6 and a median of -$46609.0 in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income slumped 66.21% — and 2025, when it jumped 365.51%.
- China Pharma Holdings' Non Operating Income stood at -$95172.0 in 2022, then jumped by 49.86% to -$47722.0 in 2023, then surged by 40.5% to -$28396.0 in 2024, then increased by 22.74% to -$21940.0 in 2025, then retreated by 17.98% to -$25884.0 in 2026.
- Business Quant data shows CPHI's Non Operating Income at -$25884.0 in Q1 2026, -$21940.0 in Q4 2025, and -$23337.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | -25,884.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25,884.00 |
| Dec 31, 2025 | -21,940.00 |
| Sep 30, 2025 | -23,337.00 |
| Jun 30, 2025 | 123,753.00 |
| Mar 31, 2025 | -26,954.00 |
| Dec 31, 2024 | -28,396.00 |
| Sep 30, 2024 | -32,654.00 |
| Jun 30, 2024 | -46,609.00 |
| Mar 31, 2024 | -39,840.00 |
| Dec 31, 2023 | -47,722.00 |
| Sep 30, 2023 | -64,058.00 |
| Jun 30, 2023 | -136,721.00 |
| Mar 31, 2023 | -78,497.00 |
| Dec 31, 2022 | -95,172.00 |
| Sep 30, 2022 | -102,119.00 |
| Jun 30, 2022 | -108,801.00 |
| Mar 31, 2022 | -117,772.00 |
| Dec 31, 2021 | -332,029.00 |
| Sep 30, 2021 | -64,265.00 |
| Jun 30, 2021 | -71,813.00 |